Trevi Therapeutics, Inc.
TRVI
$6.20
$0.010.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 25.52% | 1.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.31% | -13.09% | |||
| Operating Income | 6.31% | 13.09% | |||
| Income Before Tax | 9.19% | 14.12% | |||
| Income Tax Expenses | -168.75% | 151.61% | |||
| Earnings from Continuing Operations | 9.42% | 13.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.42% | 13.80% | |||
| EBIT | 6.31% | 13.09% | |||
| EBITDA | 6.33% | 13.14% | |||
| EPS Basic | 18.38% | 17.60% | |||
| Normalized Basic EPS | 18.15% | 17.95% | |||
| EPS Diluted | 18.38% | 17.60% | |||
| Normalized Diluted EPS | 18.15% | 17.95% | |||
| Average Basic Shares Outstanding | 10.94% | 4.67% | |||
| Average Diluted Shares Outstanding | 10.94% | 4.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||